Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | The curative potential of alloSCT in the treatment of HR-MDS

Jurjen Versluis • 22 Apr 2024
EBMT 2024
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes

Jurjen Versluis, MD, PhD, Erasmus MC Cancer Institute, Rotterdam, Netherlands, highlights the advantages of allogeneic stem cell transplantation (alloSCT) for patients with high-risk myelodysplastic syndromes (HR-MDS). AlloSCT is the only potentially curative treatment that can halt progression to acute myeloid leukemia (AML), even for those with TP53-mutated MDS, though long-term survival remains challenging in this group. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jurjen Versluis

1:46
Assessing PFS and alternative endpoints for advanced cancer clinical trials
Jurjen Versluis • 22 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024

Related Videos

2:05
CAR T-cell therapy programs to improve access for patients with leukemia in Mexico
Alberto Olaya-Vargas • 15 Apr 2024
14:43
Current research into post-alloSCT maintenance therapy in AML
Ali Bazarbachi • 3 May 2024
5:20
Targeted therapies in AML: menin, FLT3 and IDH inhibitors
Felicitas Thol • 19 Apr 2024
4:15
Using MRD to guide post-alloSCT treatment decisions in AML
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals